Ben E.E.M. van den Borne

Radboud University Nijmegen — Netherlands

Medicine · Health Sciences

19h-index2.9kcitations39works2.72yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(17), Lung Cancer Research Studies(16), Lung Cancer Diagnosis and Treatment(10), Chronic Obstructive Pulmonary Disease (COPD) Research(5), Bone health and osteoporosis research(4)

Publications39 total

Association of metabolic tumour volume (MTV) and total lesion glycolysis (TLG) with survival in patients with oligometastatic non-small-cell lung cancer treated with immunotherapy: a multicentre retrospective study
European Journal of Nuclear Medicine and Molecular Imaging·2025
The Toxicity Profile of Pemetrexed in Non-Small Cell Lung Cancer Patients With Moderate Renal Impairment: A Retrospective Cohort Study
Clinical Lung Cancer·2025· 1 citedOpen Access
Opportunities for Precision Dosing of Cytotoxic Drugs in Non-Small Cell Lung Cancer: Bridging the Gap in Precision Medicine
Clinical Pharmacokinetics·2025· 6 citedOpen Access
Impact of Immune Checkpoint Inhibitors and Local Radical Treatment on Survival Outcomes in Synchronous Oligometastatic NSCLC
JTO Clinical and Research Reports·2025· 3 citedOpen Access
Development and Portability of a Text Mining Algorithm for Capturing Disease Progression in Electronic Health Records of Patients With Stage IV Non–Small Cell Lung Cancer
JCO Clinical Cancer Informatics·2024Open Access
An Evidence-Based Rationale for Dose De-escalation of Subcutaneous Atezolizumab
Targeted Oncology·2024· 3 citedOpen Access
Blood based kinase activity profiling to predict response to immune checkpoint inhibitors in patients with advanced stage non-small cell lung cancer: The IOpener study.
Journal of Clinical Oncology·2024
Open communication between patients and relatives about illness & death in advanced cancer—results of the eQuiPe Study
Supportive Care in Cancer·2024· 8 citedOpen Access
Strengths and challenges in current lung cancer care: Timeliness and diagnostic procedures in six Dutch hospitals
Lung Cancer·2024· 3 citedOpen Access
Open Communication between Patients and Relatives about Illness & Death in Advanced Cancer – Results of the eQuiPe Study
Research Square (Research Square)·2023Open Access
The Effects of Artificial Intelligence Assistance on the Radiologists’ Assessment of Lung Nodules on CT Scans: A Systematic Review
Journal of Clinical Medicine·2023· 23 citedOpen Access
Liquid biopsy-based decision support algorithms for diagnosis and subtyping of lung cancer
Lung Cancer·2023· 29 citedOpen Access
The association of body mass index with safety and effectiveness of first-line carboplatin-based chemotherapy in patients with metastatic non-small cell lung cancer
Cancer Treatment and Research Communications·2022· 5 citedOpen Access
Randomised controlled trial of first-line tyrosine-kinase inhibitor (TKI)<i>versus</i>intercalated TKI with chemotherapy for<i>EGFR</i>-mutated nonsmall cell lung cancer
ERJ Open Research·2022· 10 citedOpen Access
Life-prolonging treatment restrictions and outcomes in patients with cancer and COVID-19: an update from the Dutch Oncology COVID-19 Consortium
European Journal of Cancer·2021· 9 citedOpen Access
Late Breaking Abstract - Randomized phase III study of erlotinib compared to intercalated erlotinib with cisplatin and pemetrexed as first-line therapy for advanced EGFR mutated non-small cell lung cancer, the NVALT 17 study
Lung Cancer·2021
Dutch Oncology COVID-19 consortium: Outcome of COVID-19 in patients with cancer in a nationwide cohort study
European Journal of Cancer·2020· 77 citedOpen Access
Correction of the NSE concentration in hemolyzed serum samples improves its diagnostic accuracy in small-cell lung cancer
Oncotarget·2020· 16 citedOpen Access
Utilization of Molecular Testing and Survival Outcomes of Treatment with First- or Second-line Tyrosine Kinase Inhibitors in Advanced Non-small Cell Lung Cancer in a Dutch Population
Anticancer Research·2018· 19 citedOpen Access
Patient reported outcomes following stereotactic ablative radiotherapy or surgery for stage IA non-small-cell lung cancer: Results from the ROSEL multicenter randomized trial
Radiotherapy and Oncology·2015· 98 cited
page 1 of 2Next →

Frequent Co-authors

Harry J.M. Groen(8), Anne‐Marie C. Dingemans(7), Egbert F. Smit(7), Lizza Hendriks(6), Jos A. Stigt(6), Lidwien Graat‐Verboom(5), Emiel F.�M. Wouters(5), Frank W.J.M. Smeenk(5), Martijn A. Spruit(5), Gerarda J.M. Herder(5), Anthonie J. van der Wekken(5), Maarten J. Deenen(5), T. Jeroen N. Hiltermann(4), Gerben Bootsma(4), Hanneke W.M. van Laarhoven(4), Cor H. van der Leest(4), Cordula Pitz(4), Susan C. van ‘t Westeinde(4), Anne S. R. van Lindert(4), Wouter H. van Geffen(4)